Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
350
Trial Sponsor
Clinical Trial Start Date
January 15, 2021
0Primary Completion Date
August 1, 2022
0Study Completion Date
March 1, 2023
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Prevention0
Intervention Type
Biological0
Intervention Name
Posoleucel (ALVR105)0
Interventional Trial Phase
Phase 30
Phase 20
Participating Facility
Official Name
Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant0
Last Updated
May 5, 2022
0Allocation Type
NA0
Intervention Model
Single Group Assignment0
Masking Type
None (Open Label)0
Study summary
This is a Phase 2 study to evaluate posoleucel (ALVR105, formerly Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
